Connect with us

Politics

Congressman Raising Money To Legalize Psychedelic Mushroom Therapy

Published

on

A chief advocate for marijuana reform in Congress is formally throwing his support behind an Oregon initiative to legalize psilocybin mushrooms for therapeutic purposes and is helping to raise money for the campaign.

In an email blast, Rep. Earl Blumenauer (D-OR) wrote on Monday said that he supports the measures “because it tackles an important issue in our community, mental health, and it does so in an innovative and responsible way.”

“Measure 109 gives Oregonians who suffer from depression and anxiety the opportunity to overcome their mental health challenges through a program designed for safety and support,” the congressman said. “It’s healthcare policy done right, and it will help thousands.”

“Measure 109 will offer hope in the form of a breakthrough treatment option in Oregon: psilocybin therapy. Research at America’s top universities shows that psilocybin therapy can help people suffering from depression, anxiety, and addiction. Developed with therapeutic and mental health experts, Measure 109 brings this treatment to Oregon through a licensed, research-based system that supports and protects those in urgent need.

One potential benefit is particularly encouraging to me. In Congress, I have worked hard to deliver better end-of-life care to all Americans. Studies are showing that psilocybin therapy can help address the profound end-of-life depression and anxiety that can come with a terminal diagnosis. Anyone who has had to confront that issue themselves or with a loved one understands how devastating it can be. Measure 109 is an opportunity to continue Oregon’s leadership on improving end-of-life care.”

Blumenauer first expressed support for the psilocybin initiative during an interview with Marijuana Moment in January. It’s a notable endorsement considering how few congressional lawmakers have backed psychedelics reform, despite a growing localized movement to decriminalize entheogenic substances in cities across the country.

Rep. Joe Kennedy III (D-MA), who previously stood opposed to marijuana reform but now supports legalization, recently said that he sees potential in the therapeutic benefits of psychedelics.

In the new email blast, Blumenauer said legalizing psilocybin therapy is “an important tool, and it deserves your support.”

“This Measure can win in November, it just needs the resources to educate voters about its benefits and protections,” he said. “To do that, the campaign needs resources.”

While the U.S. might be slow to pursue psychedelics reform at the federal level, the country’s neighbor up north appears more open minded to certain policy changes around the issue.

The Canadian government will have to officially respond to a petition calling for the decriminalization of psychedelics after it recently garnered nearly 15,000 signatures—and there’s legislation in the works that could make the reform happen.

Also in Canada, the health minister this month granted exceptions for four cancer patients to use psilocybin mushrooms for end-of-life care in a landmark decision.

Last year, a Canadian House of Commons committee similarly called for the government to decriminalize the simple possession of all drugs in an effort to address addiction as a public health issue.

In the U.S. last year, Denver became the first U.S. city to decriminalize psilocybin, with the approval of a local ballot measure. Soon after, officials in Oakland, California, decriminalized possession of all plant- and fungi-based psychedelics. The City Council in Santa Cruz, California, voted to make the enforcement of laws against psychedelics among the city’s lowest enforcement priorities in January.

A measure to effectively decriminalize a wide range of psychedelics has officially qualified for the November ballot in Washington, D.C.

The Multidisciplinary Association for Psychedelic Studies announced last week that it has raised $30 million in donations—including from several notable business leaders outside the drug policy realm—that will enable it to complete a study on using MDMA to treat post-traumatic stress disorder.

Meanwhile, Oregon voters will also see a separate measure on their November ballots to decriminalize drug possession and fund treatment services.

Here’s the full text of Blumenauer’s message on the Oregon psilocybin initiative: 

“This is Congressman Earl Blumenauer and I am writing to encourage you to vote Yes on Measure 109, the psilocybin therapy measure. I support 109 because it tackles an important issue in our community, mental health, and it does so in an innovative and responsible way. Measure 109 gives Oregonians who suffer from depression and anxiety the opportunity to overcome their mental health challenges through a program designed for safety and support.

It’s healthcare policy done right, and it will help thousands.

As an Oregon legislator, a local government leader, and a United States Congressman, I’ve spent much of my public life advocating for better health care—from universal coverage, to better end of life care, to opening up research into the therapeutic benefits of medicines that have been unwisely blocked at the federal level.

Those same values are why I strongly support Ballot Measure 109 and hope you will join me in voting yes.

Measure 109 will offer hope in the form of a breakthrough treatment option in Oregon: psilocybin therapy. Research at America’s top universities shows that psilocybin therapy can help people suffering from depression, anxiety, and addiction. Developed with therapeutic and mental health experts, Measure 109 brings this treatment to Oregon through a licensed, research-based system that supports and protects those in urgent need.

One potential benefit is particularly encouraging to me. In Congress, I have worked hard to deliver better end-of-life care to all Americans. Studies are showing that psilocybin therapy can help address the profound end-of-life depression and anxiety that can come with a terminal diagnosis. Anyone who has had to confront that issue themselves or with a loved one understands how devastating it can be. Measure 109 is an opportunity to continue Oregon’s leadership on improving end-of-life care.

I also appreciate that Measure 109 was carefully and responsibly written by therapeutic and mental health experts, with extensive safeguards and oversight by the Oregon Health Authority.

Measure 109 is an important tool, and it deserves your support. This Measure can win in November, it just needs the resources to educate voters about its benefits and protections. To do that, the campaign needs resources. Contribute to Measure 109 today and help them reach voters with their message of healing.

Thank you in advance for your support—please be active on this measure—it can succeed with your help.

Best,

Rep. Earl Blumenauer”

Vermont Lawmakers Approach Legal Marijuana Sales Agreement Amid Conference Negotiations

Photo courtesy of Wikimedia/Mushroom Observer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Politics

Alabama Senate Approves Medical Marijuana Legalization Bill

Published

on

The Alabama Senate on Wednesday approved a bill to legalize medical marijuana in the state.

Weeks after the chamber’s Judiciary Committee advanced the legislation, it cleared the full floor in a vote of 21-8 following a brief, 15-minute discussion.

The bill, sponsored by Sen. Tim Melson (R), would allow people with qualifying conditions to access cannabis for therapeutic purposes.

Melson is the same lawmaker who sponsored a similar bill that was approved by the full Senate last year but which later died without a House vote amid the coronavirus pandemic.

This latest proposal would establish an 11-member Alabama Medical Cannabis Commission to implement regulations and oversee licensing.

To qualify for the program, patients would have to be diagnosed with one of about 20 conditions, including anxiety, sleep disorders, post-traumatic stress disorder and intractable pain. Regulators would not be able to independently add additional conditions, leaving that decision up to lawmakers.

Advocates say they’re encouraged that medical cannabis reform is advancing in Alabama, but they’ve raised concerns about a number of aspects of the bill.

One problematic provision, they say, is that patients with chronic or intractable pain could only be recommended medical marijuana in cases where “conventional therapeutic intervention and opiate therapy is contraindicated or has proved ineffective.”

The bill also prohibits raw cannabis, smoking, vaping and candy or baked good products. Patients would instead be allowed to purchase capsules, lozenges, oils, suppositories and topical patches.

Patients would be allowed to purchase and possess up to “70 daily dosages of medical cannabis.” Under an amendment approved on the floor, the maximum daily dose was reduced from 75 to 50 milligrams. However, the amendment’s sponsor said it could be increased to 75 milligrams in some circumstances.

The revision also calls for a label on marijuana products to indicate that cannabis can cause drowsiness.

It also calls for a nine percent gross proceeds tax on medical marijuana sales. After covering implementation costs, 60 percent of revenue would go to the state’s general fund and 30 percent would go to research into the medical potential of cannabis.

Patients, caregivers and and medical cannabis businesses would receive legal protections under the proposal, preventing them from being penalized for activities authorized by the state.


Marijuana Moment is already tracking more than 700 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

For physicians to be able to recommend cannabis to patients, they would have to complete a four-hour continuing education course and pass an exam. The course would cost upwards of $500 and doctors would also be required to take refresher classes every two years.

Under the bill, regulators would be tasked with developing restrictions on advertising and setting quality control standards. Seed-to-sale tracking and laboratory testing would be mandated.

Other changes approved on the floor would add language to stipulate that gelatinous cannabis products cannot be sugar coated and insert provisions promoting good manufacturing practices and tamper-evident packaging.

A separate amendment that cleared the chamber added sickle cell anemia as a qualifying condition for medical marijuana.

Applications for cannabis business licenses would have to be accepted starting September 1, 2022 and then proceeded within 60 days.

The commission would be required to approve at least four cultivators, up to four processors, up to four dispensaries for the first year of implementation (more could be approved after that point depending on demand) and as many as five vertically integrated operators.

This bill’s reintroduction has been greatly anticipated by advocates. The Senate approved a separate medical cannabis bill in 2019, but the House later severely compromised it. The legislation as enacted would not have legalized patient access; rather, it set up a study commission to explore the issue and make recommendations.

The commission came back with its report in December 2019, with members recommending that medical marijuana be legalized.

The Senate’s president voted against medical cannabis in 2020 but said he is open to letting the issue advance again in the new session. Meanwhile, the House speaker said that “if the bill comes up and it has proper restrictions in it, then I’m open to at least debating it.”

There could be additional pressure on the legislature to enact legalization given that voters in neighboring Mississippi approved a medical cannabis reform initiative during the November election.

New York Marijuana Legalization Proposals Get First Joint Legislative Hearing Of 2021

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

New York Marijuana Legalization Proposals Get First Joint Legislative Hearing Of 2021

Published

on

New York lawmakers on Tuesday held the first public hearing of the year on proposals to legalize marijuana, specifically focusing on budget implications.

In a joint session with members of the Senate Finance Committee and Assembly Ways & Means Committee, legislators heard testimony from two pro-legalization industry representatives and one opponent, Kevin Sabet of the prohibitionist group Smart Approaches to Marijuana.

Notably, despite their ideological differences when it comes to legalization in general, all three panelists were critical of the reform proposal that Gov. Andrew Cuomo (D) included in his budget request.

NY Cannabis Growers and Processors Association President Allan Gandelman and NY Medical Cannabis Industry Association President Ngiste Abebe both said they favor a legalization measure out of the legislature—the Marijuana Regulation and Taxation Act (MRTA)—arguing that its tax structure and social equity provisions are superior to the governor’s plan, even after Cuomo submitted amendments in hopes of shoring up support among skeptical lawmakers.

“We deeply appreciate the possibilities offered in the MRTA. New York will need to balance issues involving taxes, licensing and speed to market,” Gandelman said. “The MRTA does an excellent job allowing for social consumption, cannabis home grow, microbusinesses, home delivery and funding for social equity applicants. These policies should be, without question, integrated into any final legislation enacted by the state.”

Watch the joint public hearing on marijuana legalization in New York below: 

Cuomo did propose amending his legalization plan to add a home delivery option and specify how social equity grants for cannabis businesses would be distributed—but advocates say it still falls short of the MRTA, sponsored by Sen. Liz Kreuger (D), chair of the Finance Committee.

Abebe, who also serves as public policy director for Columbia Care, said that her organization believes “the governor’s proposal could be improved as well—and then, between the [Cannabis Regulation and Taxation Act] and the MRTA, there is a pathway to effective legalization in New York.”

But the April 1 deadline to get those improvements included in Cuomo’s budget plan and pass the legislation is quickly approaching, and legislative leadership has indicated that they’d prefer to pass the MRTA first and then begin negotiations with the governor’s office.

“It is my hope and desire that New York will legalize adult-use of cannabis this current session in 2021,” Assembly Majority Leader Crystal Peoples-Stokes (D), who has been especially critical of the governor’s proposal, recently said.

Earlier this month, Lt. Gov. Kathy Hochul (D) told Marijuana Moment in an interview that there would be room for revisions to the governor’s plan, stating that “much of it is going to be negotiated with the legislature, and all these details can be resolved with their input as well.”


Marijuana Moment is already tracking more than 700 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

Cuomo said that the changes in his bill reflect “the conversations we’ve had, but I’m hopeful that we can come to an agreement and we can get it done. He added that he believes, “because I’ve seen this movie before, “if we don’t get it done by April 1, we won’t get it done.”

This is the third year in a row that Cuomo has included a legalization proposal in his budget plan. The last two times, negotiations with the legislature stalled amid disagreements over certain components such as the tax structure for the market and funding for social equity programs.

Regardless of which direction the legislature ultimately goes on this issue, there’s growing recognition in the state that legalization is an inevitability.

The top Republican in the New York Assembly said in December that he expects the legislature to legalize cannabis this coming session.

Senate Majority Leader Andrea Stewart-Cousins (D) said in November that she also anticipates that the reform will advance in 2021, though she noted that lawmakers will still have to decide on how tax revenue from marijuana sales is distributed.

Cuomo also said that month that the “pressure will be on” to legalize cannabis in the state and lawmakers will approve it “this year” to boost the economy amid the health crisis.

The push to legalize in New York could also be bolstered by the fact that voters in neighboring New Jersey approved a legalization referendum in November.

Separately, several other bills that focus on medical marijuana have been filed in New York, and they touch on a wide range of topics—from tenants’ rights for medical cannabis patients to health insurance coverage for marijuana products.

Biden Cabinet Pick Defends Proposal To Use Marijuana Tax Dollars To Fund Schools

Photo courtesy of WeedPornDaily.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Biden Cabinet Pick Defends Proposal To Use Marijuana Tax Dollars To Fund Schools

Published

on

President Joe Biden’s pick for secretary of the Interior Department on Tuesday defended a past campaign promise to support marijuana legalization as a means to diversify her state’s economy and help fund public education.

Rep. Deb Haaland (D-NM) was pressed on her 2018 remarks during a confirmation hearing before the Senate Energy and Natural Resources Committee. Sen. John Barrasso (R-WY), the panel’s ranking member, asked whether it was still her position that tax revenue from cannabis sales could be used to support schools as a replacement for oil and gas royalties as part of a plan to shift away from fossil fuels.

“Well, I think the point of that, ranking member, was to say that we should diversify our funding streams for education and not just rely on one,” she replied.

“Is selling marijuana among what the Biden administration calls ‘better choices’ that the Biden administration has promised to give displaced oil and gas workers?” Barrasso asked. “Is that the better choice? Marijuana?”

“I honestly don’t know what President Biden’s stance is on cannabis currently,” the nominee said.

The president’s position on marijuana does depart with Haaland’s, as he has maintained an opposition to adult-use legalization and hasn’t signaled that he’d be interested in enacting the reform as a way to raise revenue for any particular initiative. He supports legalizing medical cannabis, decriminalizing low-level marijuana possession, modestly rescheduling the plant, expunging prior cannabis convictions and letting states set their own policies.

In any case, the senator—along with the Republican National Committee (RNC), which circulated Haaland’s 2018 comments ahead of the hearing—apparently feels that the marijuana position of his nominee to head Interior are damning, despite the bipartisan public support for legalization and broad sentiment that tax revenue from cannabis should be effectively utilized for public services.

“We know what your stances on replacing the revenue, the energy jobs, the jobs that power our economy and the energy that powers our country. And your preference is to turn to drugs is what you’ve recommended to the voters,” Barrasso said. “At a time when there’s high unemployment and energy workers lose their jobs—we’ve seen it in West Virginia, we’ve seen it around the country—there’s been an opioid crisis in this nation. And yet what I hear from you is the answer in a better choice world is marijuana.”

Later in the hearing, Sen. Maria Cantwell (D-WA) returned to the ranking member’s line of questioning and said “just to be clear on the marijuana issue, this isn’t a Seattle issue. Out of 39 counties, 20 to 25 counties in the state of Washington supported legalizing cannabis.”

“I don’t blame our legislature or others from getting revenue from that and put it towards public health issues in the state of Washington,” she said. “This is respecting the wishes of the voters and then putting it to good use.”

Watch Cantwell’s marijuana comments, starting around 55:45 into the video below: 

Marijuana also came up during Haaland’s initial committee confirmation hearing on Tuesday, with Rep. Don Young (R-AK) introducing Haaland and joking about her energy policy by saying that “anybody who thinks you’re going to cut off fossil fuel immediately is smoking pot—that’s legal in the state of Alaska, by the way.”

Watch Young’s cannabis comments, about 37:00 into the video below:

For advocates, while it’s encouraging to see administration nominees embrace pro-reform positions, this was not the most consequential cannabis comment during a confirmation session this week. On Monday, Merrick Garland, the president’s nominee for attorney general said it is not “a useful use of limited resources” to go after people who are complying with state marijuana laws. He also citied cannabis enforcement as an example of the racially discriminatory impact of the criminal justice system.

Another New Mexico House Committee Approves Marijuana Legalization Bill

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment